Cargando…

MSH2 and CXCR4 involvement in malignant VIPoma

BACKGROUND: Vasoactive intestinal polypeptide secreting tumors(VIPomas) are rare endocrine tumors of the pancreas with an estimated incidence of 0.1 per million per year. The molecular mechanisms that mediate development of VIPomas are poorly investigated and require definition. METHODS: A genome- a...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Sven, Kupka, Susan, Königsrainer, Ingmar, Northoff, Hinnak, Sotlar, Karl, Bock, Thomas, Kandolf, Reinhard, Traub, Frank, Königsrainer, Alfred, Zieker, Derek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544679/
https://www.ncbi.nlm.nih.gov/pubmed/23231927
http://dx.doi.org/10.1186/1477-7819-10-264
_version_ 1782255827071008768
author Müller, Sven
Kupka, Susan
Königsrainer, Ingmar
Northoff, Hinnak
Sotlar, Karl
Bock, Thomas
Kandolf, Reinhard
Traub, Frank
Königsrainer, Alfred
Zieker, Derek
author_facet Müller, Sven
Kupka, Susan
Königsrainer, Ingmar
Northoff, Hinnak
Sotlar, Karl
Bock, Thomas
Kandolf, Reinhard
Traub, Frank
Königsrainer, Alfred
Zieker, Derek
author_sort Müller, Sven
collection PubMed
description BACKGROUND: Vasoactive intestinal polypeptide secreting tumors(VIPomas) are rare endocrine tumors of the pancreas with an estimated incidence of 0.1 per million per year. The molecular mechanisms that mediate development of VIPomas are poorly investigated and require definition. METHODS: A genome- and gene expression analysis of specimens of a primary pancreatic VIPoma with hepatic metastases was performed. The primary tumor, the metastases, the corresponding healthy tissue of the liver, and the pancreas were compared with each other using oligonucleotide microarrays and loss of heterozygosity (LOH). RESULTS: The results revealed multiple LOH events and several differentially expressed genes. Our finding of LOH and downregulation was conspicuous in the microarray analysis for the mismatch repair gene MSH2 in the primary pancreatic VIPoma tumor, the hepatic metastasis but not in the corresponding healthy tissue. Further a strong overexpression of the chemokine CXCR4 was detected in the hepatic metastases compared to its pancreatic primary. With a review of the literature we describe the molecular insights of metastatic development in VIPoma. CONCLUSION: In VIPoma, defects in the mismatch repair system especially in MSH2 may contribute to carcinogenesis, and increased CXCR4 may be associated with liver metastasis.
format Online
Article
Text
id pubmed-3544679
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35446792013-01-16 MSH2 and CXCR4 involvement in malignant VIPoma Müller, Sven Kupka, Susan Königsrainer, Ingmar Northoff, Hinnak Sotlar, Karl Bock, Thomas Kandolf, Reinhard Traub, Frank Königsrainer, Alfred Zieker, Derek World J Surg Oncol Research BACKGROUND: Vasoactive intestinal polypeptide secreting tumors(VIPomas) are rare endocrine tumors of the pancreas with an estimated incidence of 0.1 per million per year. The molecular mechanisms that mediate development of VIPomas are poorly investigated and require definition. METHODS: A genome- and gene expression analysis of specimens of a primary pancreatic VIPoma with hepatic metastases was performed. The primary tumor, the metastases, the corresponding healthy tissue of the liver, and the pancreas were compared with each other using oligonucleotide microarrays and loss of heterozygosity (LOH). RESULTS: The results revealed multiple LOH events and several differentially expressed genes. Our finding of LOH and downregulation was conspicuous in the microarray analysis for the mismatch repair gene MSH2 in the primary pancreatic VIPoma tumor, the hepatic metastasis but not in the corresponding healthy tissue. Further a strong overexpression of the chemokine CXCR4 was detected in the hepatic metastases compared to its pancreatic primary. With a review of the literature we describe the molecular insights of metastatic development in VIPoma. CONCLUSION: In VIPoma, defects in the mismatch repair system especially in MSH2 may contribute to carcinogenesis, and increased CXCR4 may be associated with liver metastasis. BioMed Central 2012-12-11 /pmc/articles/PMC3544679/ /pubmed/23231927 http://dx.doi.org/10.1186/1477-7819-10-264 Text en Copyright ©2012 Muller et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Müller, Sven
Kupka, Susan
Königsrainer, Ingmar
Northoff, Hinnak
Sotlar, Karl
Bock, Thomas
Kandolf, Reinhard
Traub, Frank
Königsrainer, Alfred
Zieker, Derek
MSH2 and CXCR4 involvement in malignant VIPoma
title MSH2 and CXCR4 involvement in malignant VIPoma
title_full MSH2 and CXCR4 involvement in malignant VIPoma
title_fullStr MSH2 and CXCR4 involvement in malignant VIPoma
title_full_unstemmed MSH2 and CXCR4 involvement in malignant VIPoma
title_short MSH2 and CXCR4 involvement in malignant VIPoma
title_sort msh2 and cxcr4 involvement in malignant vipoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544679/
https://www.ncbi.nlm.nih.gov/pubmed/23231927
http://dx.doi.org/10.1186/1477-7819-10-264
work_keys_str_mv AT mullersven msh2andcxcr4involvementinmalignantvipoma
AT kupkasusan msh2andcxcr4involvementinmalignantvipoma
AT konigsraineringmar msh2andcxcr4involvementinmalignantvipoma
AT northoffhinnak msh2andcxcr4involvementinmalignantvipoma
AT sotlarkarl msh2andcxcr4involvementinmalignantvipoma
AT bockthomas msh2andcxcr4involvementinmalignantvipoma
AT kandolfreinhard msh2andcxcr4involvementinmalignantvipoma
AT traubfrank msh2andcxcr4involvementinmalignantvipoma
AT konigsraineralfred msh2andcxcr4involvementinmalignantvipoma
AT ziekerderek msh2andcxcr4involvementinmalignantvipoma